دورية أكاديمية
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
| العنوان: | Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer |
|---|---|
| المؤلفون: | Landi, Lorenza, D'Incà, Federica, Gelibter, Alain, Chiari, Rita, Grossi, Francesco, Delmonte, Angelo, Passaro, Antonio, Signorelli, Diego, Gelsomino, Francesco, Galetta, Domenico, Giannarelli, Diana, Soto Parra, Hector, Minuti, Gabriele, Tiseo, Marcello, Migliorino, Maria Rita, Cognetti, Francesco, Toschi, Luca, Bidoli, Paolo, Piantedosi, Francovito, Calabro', Luana, Cappuzzo, Federico |
| المساهمون: | Landi, Lorenza, D'Incà, Federica, Gelibter, Alain, Chiari, Rita, Grossi, Francesco, Delmonte, Angelo, Passaro, Antonio, Signorelli, Diego, Gelsomino, Francesco, Galetta, Domenico, Giannarelli, Diana, Soto Parra, Hector, Minuti, Gabriele, Tiseo, Marcello, Migliorino, Maria Rita, Cognetti, Francesco, Toschi, Luca, Bidoli, Paolo, Piantedosi, Francovito, Calabro', Luana, Cappuzzo, Federico |
| سنة النشر: | 2019 |
| المجموعة: | IRInSubria - Institutional Repository Insubria (Università degli Studi dell’Insubria) |
| مصطلحات موضوعية: | Bone metastase, Immunotherapy, Nivolumab, Non-small-cell lung cancer, PD-L1, Adult, Aged, 80 and over, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Bone Neoplasm, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Cohort Studie, Female, Human, Lung Neoplasm, Male, Middle Aged, Prognosi, Treatment Outcome, Molecular Targeted Therapy |
| الوصف: | Background Bone metastases (BoM) are a negative prognostic factor in non-small-cell lung cancer (NSCLC). Beyond its supportive role, bone is a hematopoietic organ actively regulating immune system. We hypothesized that BoM may influence sensitivity to immunotherapy. Methods Pretreated non-squamous (cohort A) and squamous (cohort B) NSCLCs included in the Italian Expanded Access Program were evaluated for nivolumab efficacy according to BoM. Results Cohort A accounted for 1588 patients with non-squamous NSCLC, including 626 (39%) with (BoM+) and 962 (61%) without BoM (BoM-). Cohort B accounted for 371 patients with squamous histology including 120 BoM+ (32%) and 251 (68%) BoM- cases. BoM+ had lower overall response rate (ORR; Cohort A: 12% versus 23%, p < 0.0001; Cohort B: 13% versus 22%, p = 0.04), shorter progression free survival (PFS; Cohort A: 3.0 versus 4.0 months, p < 0.0001; Cohort B: 2.7 versus 5.2 months, p < 0.0001) and overall survival (OS; Cohort A: 7.4 versus 15.3 months, p < 0.0001; Cohort B: 5.0 versus 10.9 months, p < 0.0001). Moreover, BoM negatively affected outcome irrespective of performance status (PS; OS in both cohorts: p < 0.0001) and liver metastases (OS cohort A: p < 0.0001; OS Cohort B: p = 0.48). At multivariate analysis, BoM independently associated with higher risk of death (cohort A: HR 1.50; cohort B: HR 1.78). Conclusions BoM impairs immunotherapy efficacy. Accurate bone staging should be included in clinical trials with immunotherapy. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/31752994; info:eu-repo/semantics/altIdentifier/wos/WOS:000501612400007; volume:7; issue:1; firstpage:1; lastpage:9; numberofpages:9; journal:JOURNAL FOR IMMUNOTHERAPY OF CANCER; https://hdl.handle.net/11383/2141996Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85075518457 |
| DOI: | 10.1186/s40425-019-0793-8 |
| الإتاحة: | https://doi.org/10.1186/s40425-019-0793-8Test https://hdl.handle.net/11383/2141996Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.BCBBB13B |
| قاعدة البيانات: | BASE |
| DOI: | 10.1186/s40425-019-0793-8 |
|---|